<DOC>
	<DOCNO>NCT00102115</DOCNO>
	<brief_summary>The purpose study determine safety tolerability Talaporfin Sodium ( LS11 ) Photodynamic Therapy patient late stage Age-Related Macular Disease ( AMD ) .</brief_summary>
	<brief_title>Study Talaporfin Sodium Photodynamic Therapy Treat Advanced Age Related Macular Disease</brief_title>
	<detailed_description>This Phase 1 study safety tolerability investigation LS11 photodynamic therapy subject persistent leak neovascular membrane patient AMD visual acuity 20/200 less . This sequential group dose escalation trial cohort define increase light dose . Within light-dose cohort , three ( 3 ) subject treat drug dose 0.2 mg/kg 0.5 mg/kg .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Talaporfin</mesh_term>
	<criteria>Age 50 old Subject able sign inform consent Ability complete 6 month trial Present advance AMD persistently leak CNV Adequate hematologic , renal liver function Negative pregnancy test Subject able safely undertake protocol direct instruction Visual acuity 20/200 ( logMAR 1.0 ) ( 6/60 ) bad Concomitant eye disease eye treat Prior ocular radionuclide treatment Known allergic hypersensitivity reaction light and/or fluorescein iodine shellfish History investigational drug therapy include biologics within 30 day prior study drug dose Women pregnant lactating , woman childbearing year take adequate contraception precaution History porphyria , systemic lupus erythematosus , xeroderma pigmentosum History clinically significant cardiovascular abnormality , include myocardial infarction past 6 month , uncontrolled arrhythmia , uncontrolled congestive heart failure Concomitant use drug know produce skin photosensitivity , e.g . tetracycline , sulfonamide , phenothiazine , sulfonylurea , thiazide diuretic griseofulvin , St. John 's Wort Subjects high pathological myopia axial length &gt; 26mm refractive error &gt; /= 8.00D Subjects glaucoma vision loss either eye Subject history choroidal leakage , e.g . histoplasmosis Subjects significant medium opacity Subjects diagnose diabetic retinopathy Subjects eye surgery within past 3 month Subjects receive PDT treatment AMD treatment eye Any disease condition sponsor investigator believe impact subject 's ability adhere study schedule Subjects participate concurrent trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Macular disease</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>AMD</keyword>
	<keyword>Age-Related Macular Disease</keyword>
	<keyword>PDT</keyword>
	<keyword>Photodynamic Therapy</keyword>
</DOC>